Skip to content
  1. Home
  2. News
  3. Reata Pharmaceuticals and Blackstone Life Sciences Announce $350M Strategic Investment

Reata Pharmaceuticals and Blackstone Life Sciences Announce $350M Strategic Investment

Deals & Cases
June 11, 2020
Download PDF

Vinson & Elkins served as co-counsel to Reata Pharmaceuticals, Inc. in connection with a $350 million royalty and equity investment in Reata led by funds managed by Blackstone Life Sciences to fund the development and potential commercialization of bardoxolone methyl, an investigational once-daily oral therapy being studied for chronic kidney disease in Alport syndrome, autosomal dominant polycystic kidney disease and other associated potential future indications.

The financing also includes a $50 million investment in 340,793 shares of Reata’s Class A common stock at $146.72 per share. Reata will receive the $350 million investment at closing, which is expected to occur on or before June 24, 2020.

The V&E team was led by partner Robert Kimball with assistance from senior associate Katherine Frank and associate Breanna Kelly.

For more information, please speak with our media contacts.

Key Contacts